真实世界中影响类风湿关节炎患者使用托珠单抗单药治疗的因素:ACT-SOLO研究1年结果
ACT-SOLO是一项非干预性、前瞻性、全国性、多中心研究,纳入577例开始托珠单抗治疗的类风湿关节炎患者,其中40%接受单药治疗。单药治疗的解释因素包括年龄≥65岁、近两年未使用甲氨蝶呤、既往严重感染和基线DAS28-ESR较高;1年时单药与联合治疗患者的临床结果相似,严重感染发生率为4%。
要点
- 真实世界中40%的RA患者使用托珠单抗单药治疗。
- 单药治疗预测因素:年龄≥65岁、近两年未用MTX、既往严重感染、高基线DAS28-ESR。
- 1年时单药与联合治疗的临床结果和安全性无显著差异。
核心结论
- ACT-SOLO研究证实临床实践中相当高比例的RA患者接受托珠单抗单药治疗。
- 真实世界环境中,单药与联合治疗患者1年临床结果相似。
研究设计与样本
- 非干预性、前瞻性、全国性、多中心研究,每3个月收集数据,持续12个月。
- 纳入577例开始托珠单抗治疗的RA患者,招募时间为2012年1月至2013年8月。
主要发现
- 577例分析患者中228例(40%)为单药治疗;79%为女性,平均RA病程11±9年,75%既往使用过bDMARDs和csDMARDs,基线平均DAS28-ESR为5.2±1.3。
- 单药治疗的预测因素:年龄≥65岁(OR=1.47,p=0.0485)、近两年未使用甲氨蝶呤(OR=5.96,p<0.0001)、既往严重感染(OR=1.99,p=0.0272)、较高基线DAS28-ESR(OR=1.22,p=0.0086)。
- 1年时单药与联合治疗患者在DAS28-ESR、CDAI、SDAI低疾病活动度和缓解、ACR20/50/70和EULAR反应、HAQ-DI评分方面无相关差异。
- 23例(4%)托珠单抗治疗患者发生严重感染,未发现新安全性信号,组间无差异。
关键数值与推荐
- 单药治疗预测因素:年龄≥65岁(OR=1.47,p=0.0485)。
- 近两年未使用甲氨蝶呤(OR=5.96,p<0.0001)。
- 既往严重感染(OR=1.99,p=0.0272)。
- 较高基线DAS28-ESR(OR=1.22,p=0.0086)。
临床怎么用
- 临床实践中托珠单抗单药治疗常用于高龄、MTX不耐受/未使用、有严重感染史或高疾病活动度的RA患者。
- 单药与联合治疗1年疗效和安全性相似,支持在特定患者中选择单药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. This study mainly aimed to search for real-life factors influencing the use of tocilizumab as MONO or in combination (COMBO). METHODS: In this non-interventional, prospective, national, multicentre study, data were collected every 3 months over a 12-month period in RA patients starting tocilizumab. The proportion of monotherapy patients was described, together with significant explicative factors. RESULTS: Among the 577 analysed patients recruited from January 2012 to August 2013 (228 monotherapy patients; 40%), 79% were women, mean RA duration was 11±9 years, previous RA treatments included bDMARDs and csDMARDs in 75% of cases and mean Disease Activity Score 28 joints-Erythrocyte Sedimentation Rate (DAS28-ESR) was 5.2±1.3 at inclusion. Explicative factors for monotherapy were at least 65 years (OR=1.47, p=0.0485), no methotrexate within the two last years (OR=5.96, p<0.0001), past severe infection (OR=1.99, p=0.0272) and higher baseline DAS28-ESR (OR=1.22, p=0.0086). Regarding clinical results (DAS28-ESR, Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) low disease activity and remission; ACR20/50/70 and European League Against Rheumatism (EULAR) response; Health Assessment Questionnaire Disability Index (HAQ-DI) score), no relevant differences between monotherapy and combination patients were observed at 1 year. A total of 23 tocilizumab-treated patients (4%) experienced serious infections; no new safety signals were noted with no differences between groups. CONCLUSIONS: ACT-SOLO confirms the high proportion of RA patients receiving tocilizumab as MONO in clinical practice. The study also showed that clinical results at 1 year were similar between MONO and COMBO patients in a real-life setting. TRIAL REGISTRATION NUMBER: NCT01474291.
引用
- Flipo RM, Maillefert JF, Chazerain P, et al. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open. 2017. PMID: 28123778. doi:10.1136/rmdopen-2016-000340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。